The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
Open accessAbstract
Using current diagnostic criteria, primary mediastinal B cell lymphoma (PMBL) cannot be distinguished from other types of diffuse large B cell lymphoma (DLBCL) reliably. We used gene expression profiling to develop a more precise molecular diagnosis of PMBL. PMBL patients were considerably younger than other DLBCL patients, and their lymphomas frequently involved other thoracic structures but not extrathoracic sites typical of other DLBCLs. PMBL patients had a relatively favorable clinical outcome, with a 5-yr survival rate of 64% compared with 46% for other DLBCL patients. Gene expression profiling strongly supported a relationship between PMBL and Hodgkin lymphoma: over one third of the genes that were more highly expressed in PMBL than in other DLBCLs were also characteristically expressed in Hodgkin lymphoma cells. PDL2, which encodes a regulator of T cell activation, was the gene that best discriminated PMBL from other DLBCLs and was also highly expressed in Hodgkin lymphoma cells. The genomic loci for PDL2 and several neighboring genes were amplified in over half of the PMBLs and in Hodgkin lymphoma cell lines. The molecular diagnosis of PMBL should significantly aid in the development of therapies tailored to this clinically and pathogenetically distinctive subgroup of DLBCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Self-citationFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Self-citationPD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Wright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040
Self-citationRosenwald, A., Wright, G., Wiestner, A., Chan, W. C., Connors, J. M., Campo, E., Gascoyne, R. D., Grogan, T. M., Muller-Hermelink, H. K., Smeland, E. B., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00028-x · Cited by 914
Self-citation
Cited by
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Campo, E., Swerdlow, S. H., Harris, N. L., Pileri, S., Stein, H., & Jaffe, E. S. (2011) · Blood · doi:10.1182/blood-2011-01-293050 · Cited by 2,008
Self-citationSehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., Shenkier, T., Sutherland, J., et al. (2007) · Blood · doi:10.1182/blood-2006-08-038257 · Cited by 1,473
Self-citationTargeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
The molecular classification of multiple myeloma
Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., et al. (2006) · Blood · doi:10.1182/blood-2005-11-013458 · Cited by 1,133
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Lenz, G., Wright, G. W., Emre, N. C. T., Kohlhammer, H., Dave, S. S., Davis, R. E., Carty, S., Lam, L. T., Shaffer, A. L., Xiao, W., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804295105 · Cited by 995
Self-citationAnalysis of the coding genome of diffuse large B-cell lymphoma
Pasqualucci, L., Trifonov, V., Fabbri, G., Ma, J., Rossi, D., Chiarenza, A., Wells, V. A., Grunn, A., Messina, M., Elliot, O., et al. (2011) · Nature Genetics · doi:10.1038/ng.892 · Cited by 971
Mechanisms of B-cell lymphoma pathogenesis
Küppers, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1589 · Cited by 965
Annunziata, C. M., Davis, R. E., Demchenko, Y., Bellamy, W., Gabrea, A., Zhan, F., Lenz, G., Hanamura, I., Wright, G., Xiao, W., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.004 · Cited by 952
Self-citationMolecular Diagnosis of Burkitt's Lymphoma
Dave, S. S., Fu, K., Wright, G. W., Lam, L. T., Kluin, P., Boerma, E.-J., Greiner, T. C., Weisenburger, D. D., Rosenwald, A., Ott, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055759 · Cited by 897
Self-citationOncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma
Lenz, G., Davis, R. E., Ngo, V. N., Lam, L., George, T. C., Wright, G. W., Dave, S. S., Zhao, H., Xu, W., Rosenwald, A., et al. (2008) · Science · doi:10.1126/science.1153629 · Cited by 867
Self-citationMonti, S. (2005) · Blood · doi:10.1182/blood-2004-07-2947 · Cited by 820
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination
Klein, U., Casola, S., Cattoretti, G., Shen, Q., Lia, M., Mo, T., Ludwig, T., Rajewsky, K., & Dalla-Favera, R. (2006) · Nature Immunology · doi:10.1038/ni1357 · Cited by 801
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akinleye, A., & Rasool, Z. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0779-5 · Cited by 733
Kluiver, J., Poppema, S., de Jong, D., Blokzijl, T., Harms, G., Jacobs, S., Kroesen, B., & van den Berg, A. (2005) · The Journal of Pathology · doi:10.1002/path.1825 · Cited by 672
Choi, W. W. L., Weisenburger, D. D., Greiner, T. C., Piris, M. A., Banham, A. H., Delabie, J., Braziel, R. M., Geng, H., Iqbal, J., Lenz, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0113 · Cited by 642
Self-citationJaffe, E. S. (2009) · Hematology · doi:10.1182/asheducation-2009.1.523 · Cited by 632
Self-citationde Leval, L., Rickman, D. S., Thielen, C., Reynies, A. D., Huang, Y.-L., Delsol, G., Lamant, L., Leroy, K., Brière, J., Molina, T., et al. (2007) · Blood · doi:10.1182/blood-2006-10-055145 · Cited by 631
Self-citationMHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers
Steidl, C., Shah, S. P., Woolcock, B. W., Rui, L., Kawahara, M., Farinha, P., Johnson, N. A., Zhao, Y., Telenius, A., Neriah, S. B., et al. (2011) · Nature · doi:10.1038/nature09754 · Cited by 615
Self-citationA loss-of-function RNA interference screen for molecular targets in cancer
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., Powell, J., et al. (2006) · Nature · doi:10.1038/nature04687 · Cited by 605
Self-citationThe 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes
Marx, A., Chan, J. K. C., Coindre, J.-M., Detterbeck, F., Girard, N., Harris, N. L., Jaffe, E. S., Kurrer, M. O., Marom, E. M., Moreira, A. L., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000654 · Cited by 603
Self-citationCheckpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 570
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214561 · Cited by 569
Self-citationThe tumour microenvironment in B cell lymphomas
Scott, D. W., & Gascoyne, R. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3774 · Cited by 552
Self-citationLenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Self-citationExploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
Yang, Y., Shaffer, A. L., Emre, N. C. T., Ceribelli, M., Zhang, M., Wright, G., Xiao, W., Powell, J., Platig, J., Kohlhammer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.024 · Cited by 521
Self-citationGerminal centres and B cell lymphomagenesis
Basso, K., & Dalla-Favera, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3814 · Cited by 510
Dunleavy, K., Pittaluga, S., Czuczman, M. S., Dave, S. S., Wright, G., Grant, N., Shovlin, M., Jaffe, E. S., Janik, J. E., Staudt, L. M., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199679 · Cited by 497
Self-citationStaudt, L. M. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000109 · Cited by 485
Self-citationArmand, P., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D. E., Chen, Y.-B., Kaminski, M. S., Holland, H. K., Winter, J. N., Mason, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3685 · Cited by 440
Pathogenesis of Human B Cell Lymphomas
Shaffer, A. L., Young, R. M., & Staudt, L. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075027 · Cited by 437
Self-citationHodgkin lymphoma and immunodeficiency in persons with HIV/AIDS
Biggar, R. J., Jaffe, E. S., Goedert, J. J., Chaturvedi, A., Pfeiffer, R., Engels, E. A., & Study, F. T. H. C. M. (2006) · Blood · doi:10.1182/blood-2006-05-024109 · Cited by 436
Self-citationPD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Xu-Monette, Z. Y., Zhou, J., & Young, K. H. (2018) · Blood · doi:10.1182/blood-2017-07-740993 · Cited by 433
PD-1 and its ligands in T-cell immunity
Keir, M. E., Francisco, L. M., & Sharpe, A. H. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.04.012 · Cited by 431
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
Roschewski, M., Staudt, L. M., & Wilson, W. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.197 · Cited by 411
Self-citationAberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications
Jost, P. J., & Ruland, J. (2007) · Blood · doi:10.1182/blood-2006-07-025809 · Cited by 408
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery
Jaffe, E. S., Harris, N. L., Stein, H., & Isaacson, P. G. (2008) · Blood · doi:10.1182/blood-2008-07-077982 · Cited by 382
Self-citationAt the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
Intlekofer, A. M., & Thompson, C. B. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212621 · Cited by 371
Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia
Raval, A., Tanner, S. M., Byrd, J. C., Angerman, E. B., Perko, J. D., Chen, S.-S., Hackanson, B., Grever, M. R., Lucas, D. M., Matkovic, J. J., et al. (2007) · Cell · doi:10.1016/j.cell.2007.03.043 · Cited by 371
Self-citationInactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma
Pasqualucci, L., Compagno, M., Houldsworth, J., Monti, S., Grunn, A., Nandula, S. V., Aster, J. C., Murty, V. V., Shipp, M. A., & Dalla-Favera, R. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052204 · Cited by 370
PD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365
Non-Hodgkin Lymphoma: Diagnosis and Treatment
Ansell, S. M., & Armitage, J. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1087 · Cited by 356
Self-citationAt the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
Callahan, M. K., & Wolchok, J. D. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1212631 · Cited by 348
Fu, K., Weisenburger, D. D., Choi, W. W. L., Perry, K. D., Smith, L. M., Shi, X., Hans, C. P., Greiner, T. C., Bierman, P. J., Bociek, R. G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9277 · Cited by 334
Self-citationAndorsky, D. J., Yamada, R. E., Said, J., Pinkus, G. S., Betting, D. J., & Timmerman, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2660 · Cited by 328
Rossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., et al. (2014) · Leukemia · doi:10.1038/leu.2014.137 · Cited by 322
Self-citationWeniger, M. A., Melzner, I., Menz, C. K., Wegener, S., Bucur, A. J., Dorsch, K., Mattfeldt, T., Barth, T. F. E., & Möller, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209151 · Cited by 322
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation
Riley, J. L., & June, C. H. (2005) · Blood · doi:10.1182/blood-2004-04-1596 · Cited by 315
Twa, D. D. W., Chan, F. C., Ben-Neriah, S., Woolcock, B. W., Mottok, A., Tan, K. L., Slack, G. W., Gunawardana, J., Lim, R. S., McPherson, A. W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535443 · Cited by 302
Self-citationDing, B. B., Yu, J. J., Yu, R. Y.-L., Mendez, L. M., Shaknovich, R., Zhang, Y., Cattoretti, G., & Ye, B. H. (2008) · Blood · doi:10.1182/blood-2007-04-087734 · Cited by 298
Iqbal, J., Neppalli, V. T., Wright, G., Dave, B. J., Horsman, D. E., Rosenwald, A., Lynch, J., Hans, C. P., Weisenburger, D. D., Greiner, T. C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4264 · Cited by 298
Self-citationZinzani, P. L., Ribrag, V., Moskowitz, C. H., Michot, J.-M., Kuruvilla, J., Balakumaran, A., Zhang, Y., Chlosta, S., Shipp, M. A., & Armand, P. (2017) · Blood · doi:10.1182/blood-2016-12-758383 · Cited by 289
Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
Quintás-Cardama, A., & Verstovsek, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0284 · Cited by 284
Cooperative Epigenetic Modulation by Cancer Amplicon Genes
Rui, L., Emre, N. C. T., Kruhlak, M. J., Chung, H.-J., Steidl, C., Slack, G., Wright, G. W., Lenz, G., Ngo, V. N., Shaffer, A. L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.013 · Cited by 283
Self-citationMandelbaum, J., Bhagat, G., Tang, H., Mo, T., Brahmachary, M., Shen, Q., Chadburn, A., Rajewsky, K., Tarakhovsky, A., Pasqualucci, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.030 · Cited by 282
Iqbal, J., Sanger, W. G., Horsman, D. E., Rosenwald, A., Pickering, D. L., Dave, B., Dave, S., Xiao, L., Cao, K., Zhu, Q., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63284-1 · Cited by 279
Self-citationThieblemont, C., Briere, J., Mounier, N., Voelker, H.-U., Cuccuini, W., Hirchaud, E., Rosenwald, A., Jack, A., Sundstrom, C., Cogliatti, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4423 · Cited by 275
Self-citationMALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo
Fontan, L., Yang, C., Kabaleeswaran, V., Volpon, L., Osborne, M. J., Beltran, E., Garcia, M., Cerchietti, L., Shaknovich, R., Yang, S. N., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.11.003 · Cited by 264
Self-citationThe Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling
Staudt, L. M., & Dave, S. (2005) · Advances in Immunology · doi:10.1016/s0065-2776(05)87005-1 · Cited by 260
Self-citationImmunotherapy comes of age: Immune aging & checkpoint inhibitors
Elias, R., Karantanos, T., Sira, E., & Hartshorn, K. L. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.02.001 · Cited by 133
Janus kinase deregulation in leukemia and lymphoma
Chen, E., Staudt, L. M., & Green, A. R. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.017 · Cited by 123
Self-citationSchatz, J. H., Oricchio, E., Wolfe, A. L., Jiang, M., Linkov, I., Maragulia, J., Shi, W., Zhang, Z., Rajasekhar, V. K., Pagano, N. C., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110846 · Cited by 119
Choi, J., Lee, K., Ingvarsdottir, K., Bonasio, R., Saraf, A., Florens, L., Washburn, M. P., Tadros, S., Green, M. R., & Busino, L. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0084-5 · Cited by 50
Ferreri, A. J. M., Sassone, M., Zaja, F., Re, A., Spina, M., Rocco, A. D., Fabbri, A., Stelitano, C., Frezzato, M., Rusconi, C., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30016-9 · Cited by 32
Ceriani, L., Barrington, S., Biggi, A., Malkowski, B., Metser, U., Versari, A., Martelli, M., Davies, A., Johnson, P. W., Zucca, E., et al. (2017) · Hematological Oncology · doi:10.1002/hon.2339 · Cited by 26
Metadata
- Authors
- Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R. D., Chan, W. C., Zhao, T., Haioun, C., Greiner, T. C., Weisenburger, D. D., Lynch, J. C., Vose, J., Armitage, J. O., Smeland, E. B., Kvaloy, S., Holte, H., Delabie, J., Campo, E., Montserrat, E., Lopez-Guillermo, A., Ott, G., Muller-Hermelink, H. K., Connors, J. M., Braziel, R., Grogan, T. M., Fisher, R. I., Miller, T. P., LeBlanc, M., Chiorazzi, M., Zhao, H., Yang, L., Powell, J., Wilson, W. H., Jaffe, E. S., Simon, R., Klausner, R. D., & Staudt, L. M.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2003-09-15
- Volume
- 198
- Issue
- 6
- Pages
- 851-862
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2111500154
- Cited by
- 1,101
- References
- 23
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.